COMPARATIVE EFFICACY AND SAFETY OF RUFINAMIDE AND VALPROIC ACID MONOTHERAPY IN EPILEPSY TREATMENT DOI Creative Commons

Khalid abdulaziz alkhudaydi,

Mohammed Abdullah Alqarni,

Adnan ayidh althobaiti

et al.

Published: Jan. 1, 2022

Background: It is a well-known fact that rufinamide and valproic acid (VPA) are antiepileptic drugs (AEDs) indicated for epilepsy, but there limited data to show their relative efficacy safety. This study evaluated compared against VPA as the monotherapy choice treatment of seizures. challenge identifying right each patient with epilepsy makes it one most difficult types neurological disorders diagnose correctly manage. Methods: The 132 patients between 18-65 years age partial-onset seizures were randomized two groups which first (n=66) received up 400 mg twice daily while second extended-release 1500 during 48 weeks period. endpoints seizure reduction by 28 days (at least 50% responders' rate) freedom at 6 months, both associated quality life. Safety tolerability final important aspects well. Results: Taking 12-week treatment, rufinamide's marked median percent in frequency much higher than VPA's (45.1 vs 33.4%; p<0.0001). While more subjects group had ≥50% decrease (52.9% 33.6%, p<0.001), latter still achieved significant outcomes. consequences caused grades life scores decrease. Adverse events often similar, discontinuations occurred due side effects (3.6% 4.4%). Conclusions: effectiveness RUF have terms control remains similar; however, Rufinamide efficient, being same cases. In case Rufinamide, effect positive, this medication well-tolerated epilepsy.

Language: Английский

Imperatorin interacts additively with novel antiseizure medications in the mouse maximal electroshock-induced seizure model: an isobolographic transformation DOI Creative Commons
Jarogniew J. Łuszczki,

Ewelina Kochman-Moskal,

Hubert Bojar

et al.

Pharmacological Reports, Journal Year: 2023, Volume and Issue: 76(1), P. 216 - 222

Published: Nov. 28, 2023

Anticonvulsant effects of imperatorin (IMP) have been experimentally confirmed earlier, but no information is available on the interaction profiles this naturally occurring coumarin when combined with novel antiseizure medication (ASMs). This study aimed to determine IMP anticonvulsant lacosamide (LCM), oxcarbazepine (OXC), pregabalin (PGB), and topiramate (TPM) in maximal electroshock-induced seizure (MES) model mice. The exerted by ASMs (LCM, OXC, PGB, TPM) constant doses (25 50 mg/kg) underwent isobolographic transformation precisely classify observed interactions mouse MES model. Total brain concentrations were measured high-pressure liquid chromatography exclude pharmacokinetic nature among tested ASMs. (50 significantly enhanced (p < 0.01) potency LCM, TPM mildly potentiated action TPM, statistical significance was reported for these combinations. data from test revealed that additive. Moreover, did not affect total content any experimental additive accompanied changes are worthy recommendation further studies.

Language: Английский

Citations

0
COMPARATIVE EFFICACY AND SAFETY OF RUFINAMIDE AND VALPROIC ACID MONOTHERAPY IN EPILEPSY TREATMENT DOI Creative Commons

Khalid abdulaziz alkhudaydi,

Mohammed Abdullah Alqarni,

Adnan ayidh althobaiti

et al.

Published: Jan. 1, 2022

Background: It is a well-known fact that rufinamide and valproic acid (VPA) are antiepileptic drugs (AEDs) indicated for epilepsy, but there limited data to show their relative efficacy safety. This study evaluated compared against VPA as the monotherapy choice treatment of seizures. challenge identifying right each patient with epilepsy makes it one most difficult types neurological disorders diagnose correctly manage. Methods: The 132 patients between 18-65 years age partial-onset seizures were randomized two groups which first (n=66) received up 400 mg twice daily while second extended-release 1500 during 48 weeks period. endpoints seizure reduction by 28 days (at least 50% responders' rate) freedom at 6 months, both associated quality life. Safety tolerability final important aspects well. Results: Taking 12-week treatment, rufinamide's marked median percent in frequency much higher than VPA's (45.1 vs 33.4%; p<0.0001). While more subjects group had ≥50% decrease (52.9% 33.6%, p<0.001), latter still achieved significant outcomes. consequences caused grades life scores decrease. Adverse events often similar, discontinuations occurred due side effects (3.6% 4.4%). Conclusions: effectiveness RUF have terms control remains similar; however, Rufinamide efficient, being same cases. In case Rufinamide, effect positive, this medication well-tolerated epilepsy.

Language: Английский

Citations

0